Moleculin Biotech Inc MBRX

NAS: MBRX | ISIN: US60855D1019 26/04/2024

4,630 USD (+7,42%)

(+7,42%) 26/04/2024

Grafiek Moleculin Biotech Inc

Grafiek Moleculin Biotech Inc

1 dag1d 7,42%
1 week1w 7,67%
1 maand1m -21,66%
3 maanden3m 844,90%
6 maanden6m 919,82%
1 jaar1j 519,56%
5 jaar5j -46,78%

Moleculin Biotech Inc in het nieuws

Toon enkel gratis nieuws

18 april 2024 · European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) · Persbericht

10 april 2024 · Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties · Persbericht

28 maart 2024 · Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference · Persbericht

27 maart 2024 · Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity · Persbericht

27 maart 2024 · Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML · Persbericht

25 maart 2024 · Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial · Persbericht

22 maart 2024 · Moleculin Reports Full Year 2023 Financial Results · Persbericht

20 maart 2024 · Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast · Persbericht

19 maart 2024 · Moleculin Announces Reverse Stock Split · Persbericht

12 maart 2024 · Moleculin to Present at the 36th Annual ROTH Conference · Persbericht

Profiel Moleculin Biotech Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.moleculin.com

Hoofdzetel: Houston, Texas Verenigde Staten

Werknemers: 20

Aandelen Moleculin Biotech Inc

Beurswaarde: 10,31 miljoen USD

Effecten: 2,23 miljoen

Beta: 0,47

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe